ChemoCentryx (CCXI) Announces Quarterly Earnings Results
ChemoCentryx (NASDAQ:CCXI) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03, Fidelity Earnings reports. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. The firm had revenue of $8.98 million during the quarter, compared to the consensus estimate of $11.55 million.
ChemoCentryx stock traded down $1.65 during midday trading on Friday, hitting $10.05. 340,471 shares of the stock were exchanged, compared to its average volume of 164,306. ChemoCentryx has a 52-week low of $5.42 and a 52-week high of $15.08. The stock has a market cap of $603.72 million, a PE ratio of 27.92 and a beta of 1.78. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.69 and a current ratio of 2.69.
In related news, insider Thomas J. Schall sold 7,211 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $12.00, for a total transaction of $86,532.00. Following the transaction, the insider now directly owns 2,192,205 shares in the company, valued at $26,306,460. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Markus J. Cappel sold 30,237 shares of the business’s stock in a transaction dated Friday, October 26th. The stock was sold at an average price of $11.01, for a total transaction of $332,909.37. Following the transaction, the insider now owns 54,063 shares in the company, valued at $595,233.63. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,380,940 shares of company stock worth $86,264,863. 14.50% of the stock is owned by corporate insiders.
Several research firms have recently commented on CCXI. ValuEngine downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Thursday, September 27th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of ChemoCentryx in a research report on Monday, August 13th. BidaskClub downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Thursday, July 19th. B. Riley began coverage on shares of ChemoCentryx in a research report on Friday, September 7th. They set a “neutral” rating and a $12.50 target price for the company. Finally, Zacks Investment Research downgraded shares of ChemoCentryx from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 16th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $16.58.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2018/11/10/chemocentryx-ccxi-announces-quarterly-earnings-results.html.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Recommended Story: What is the Rule of 72?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.